TuHURA Biosciences (HURA) 10-Q 13 May 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2022	May 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	KTRA
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Registrant Name	Kintara Therapeutics, Inc.
Entity Central Index Key	0001498382
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		65,532,826
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37823
Entity Tax Identification Number	99-0360497
Entity Address, Address Line One	9920 Pacific Heights Blvd
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	350-4364
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheet - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 8,839	$ 10,537
Prepaid expenses, deposits and other	1,254	756
Clinical trial deposit		500
Total current assets	10,093	11,793
Clinical trial deposit	2,600	1,600
Property, equipment and intangibles, net	105	150
Total assets	12,798	13,543
Current liabilities
Accounts payable and accrued liabilities	2,782	2,219
Related party payables	458	561
Total current liabilities	3,240	2,780
Milestone payment liability	172	182
Total liabilities	3,412	2,962
Stockholders' equity
Common stock Authorized 175,000 shares at March 31, 2022 and June 30, 2021, $0.001 par value 49,306 issued at March 31, 2022 (June 30, 2021 - 32,740)	49	33
Additional paid-in capital	127,670	106,821
Accumulated deficit	(130,908)	(111,225)
Accumulated other comprehensive income	21	21
Total stockholders’ equity	9,386	10,581
Total liabilities and stockholders’ equity	12,798	13,543
Preferred Stock Series A
Stockholders' equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders' equity
Preferred stock	$ 12,275	$ 14,652

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheet (Parenthetical) - $ / shares	Mar. 31, 2022	Jun. 30, 2021
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	175,000,000	175,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	49,306,000	32,740,000
Preferred Stock Series A
Preferred Stock, shares issued	279,000	279,000
Preferred stock, shares outstanding	279,000	279,000
Preferred Stock Series C
Preferred Stock, shares issued	17,000	20,000
Preferred stock, shares outstanding	17,000	20,000

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Expenses
Research and development	$ 3,474	$ 3,843	$ 11,169	$ 7,784
General and administrative	1,884	2,762	6,055	7,091
Merger costs				500
In-process research and development				16,094
Operating Expenses	(5,358)	(6,605)	(17,224)	(31,469)
Other income (loss)
Foreign exchange	1	(1)	6	(3)
Amortization of deferred loan costs		(23)		(74)
Interest, net	1	(6)	3	(20)
Other loss (income)	2	(30)	9	(97)
Net loss for the period	(5,356)	(6,635)	(17,215)	(31,566)
Computation of basic loss per share
Net loss for the period	(5,356)	(6,635)	(17,215)	(31,566)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance				(3,181)
Series A Preferred cash dividend	(2)	(2)	(6)	(6)
Net loss for the period attributable to common stockholders	$ (5,358)	$ (6,643)	$ (19,683)	$ (34,768)
Basic and fully diluted loss per share	$ (0.11)	$ (0.23)	$ (0.45)	$ (1.47)
Basic and fully diluted weighted average number of shares	49,128,000	29,273,000	43,942,000	23,701,000
Preferred Stock Series B
Computation of basic loss per share
Preferred stock dividend		$ (6)		$ (15)
Preferred Stock Series C
Computation of basic loss per share
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance				$ (3,181)
Preferred stock dividend			$ (2,462)

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit
Beginning Balance at Jun. 30, 2020	$ 263	$ 11	$ 65,148	$ 21	$ 4,804	$ (69,721)
Beginning Balance, shares at Jun. 30, 2020		11,458,000
Adgero merger (note 3)	16,725	$ 12	16,713
Adgero merger, shares		12,011,000
Issuance of Series C Preferred stock	25,028				25,028
Series C placement agent warrants			3,287		(3,287)
Series C Preferred stock share issuance costs	(3,386)				(3,386)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance			3,181			(3,181)
Exercise of warrants	994	$ 1	993
Exercise of warrants, shares		993,000
Warrants issued for services	45		45
Stock option expense	405		405
Series A Preferred cash dividend	(2)					(2)
Series B preferred stock dividend			5			(5)
Series B preferred stock dividend, shares		4,000
Loss for the period	(19,518)					(19,518)
Ending Balance at Sep. 30, 2020	20,554	$ 24	89,777	21	23,159	(92,427)
Ending Balance, shares at Sep. 30, 2020		24,466,000
Beginning Balance at Jun. 30, 2020	263	$ 11	65,148	21	4,804	(69,721)
Beginning Balance, shares at Jun. 30, 2020		11,458,000
Loss for the period	(31,566)
Ending Balance at Mar. 31, 2021	16,118	$ 32	100,828	21	19,726	(104,489)
Ending Balance, shares at Mar. 31, 2021		31,764,000
Beginning Balance at Sep. 30, 2020	20,554	$ 24	89,777	21	23,159	(92,427)
Beginning Balance, shares at Sep. 30, 2020		24,466,000
Series C Preferred stock share issuance costs	(69)				(69)
Conversion of Series B Preferred stock to common stock			268		(268)
Conversion of Series B preferred stock to common stock, shares		10,000
Conversion of Series C Preferred stock to common stock		$ 1	987		(988)
Conversion of Series C preferred stock to common stock, shares		1,168,000
Exercise of warrants	186		186
Exercise of warrants, shares		186,000
Warrants issued for services	183		183
Stock options exercised	21		21
Stock options exercised, Shares		35,000
Stock option expense	2,125		2,125
Series A Preferred cash dividend	(2)					(2)
Series B preferred stock dividend			4			(4)
Series B preferred stock dividend, shares		3,000
Loss for the period	(5,413)					(5,413)
Ending Balance at Dec. 31, 2020	17,585	$ 25	93,551	21	21,834	(97,846)
Ending Balance, shares at Dec. 31, 2020		25,868,000
Conversion of Series B Preferred stock to common stock			61		(61)
Conversion of Series B preferred stock to common stock, shares		2,000
Conversion of Series C Preferred stock to common stock		$ 3	2,115		(2,118)
Conversion of Series C preferred stock to common stock, shares		2,379,000
Series C Agent Warrants Exercised			(71)		71
Exercise of warrants	3,219	$ 3	3,216
Exercise of warrants, shares		3,478,000
Warrants issued for services	210		210
Stock options exercised	22	$ 1	21
Stock options exercised, Shares		34,000
Stock option expense	1,719		1,719
Series A Preferred cash dividend	(2)					(2)
Series B preferred stock dividend			6			(6)
Series B preferred stock dividend, shares		3,000
Loss for the period	(6,635)					(6,635)
Ending Balance at Mar. 31, 2021	16,118	$ 32	100,828	21	19,726	(104,489)
Ending Balance, shares at Mar. 31, 2021		31,764,000
Beginning Balance at Jun. 30, 2021	10,581	$ 33	106,821	21	14,931	(111,225)
Beginning Balance, shares at Jun. 30, 2021		32,740,000
Issuance of shares and warrants - net of issue costs	13,634	$ 7	13,627
Issuance of shares and warrants - net of issue costs, shares		7,200,000
Conversion of Series C Preferred stock to common stock		$ 1	1,255		(1,256)
Conversion of Series C preferred stock to common stock, shares		1,467,000
Exercise of 2020 Investor Warrants for cash	69		69
Exercise of 2020 Investor Warrants for Cash, shares		69,000
Exercise of pre-funded warrants for cash	5	$ 5
Exercise of pre-funded warrants for cash, shares		4,800,000
Warrants issued for services	31		31
Stock option expense	811		811
Series A Preferred cash dividend	(2)					(2)
Series C Preferred stock dividend		$ 2	2,460			(2,462)
Series C Preferred stock dividend, shares		1,698,000
Loss for the period	(5,966)					(5,966)
Ending Balance at Sep. 30, 2021	19,163	$ 48	125,074	21	13,675	(119,655)
Ending Balance, shares at Sep. 30, 2021		47,974,000
Beginning Balance at Jun. 30, 2021	10,581	$ 33	106,821	21	14,931	(111,225)
Beginning Balance, shares at Jun. 30, 2021		32,740,000
Loss for the period	(17,215)
Ending Balance at Mar. 31, 2022	9,386	$ 49	127,670	21	12,554	(130,908)
Ending Balance, shares at Mar. 31, 2022		49,306,000
Beginning Balance at Sep. 30, 2021	19,163	$ 48	125,074	21	13,675	(119,655)
Beginning Balance, shares at Sep. 30, 2021		47,974,000
Conversion of Series C Preferred stock to common stock		$ 1	873		(874)
Conversion of Series C preferred stock to common stock, shares		1,039,000
Warrants issued for services	4		4
Stock option expense	830		830
Series A Preferred cash dividend	(2)					(2)
Loss for the period	(5,893)					(5,893)
Ending Balance at Dec. 31, 2021	14,102	$ 49	126,781	21	12,801	(125,550)
Ending Balance, shares at Dec. 31, 2021		49,013,000
Conversion of Series C Preferred stock to common stock			247		(247)
Conversion of Series C preferred stock to common stock, shares		293,000
Stock option expense	642		642
Series A Preferred cash dividend	(2)					(2)
Loss for the period	(5,356)					(5,356)
Ending Balance at Mar. 31, 2022	$ 9,386	$ 49	$ 127,670	$ 21	$ 12,554	$ (130,908)
Ending Balance, shares at Mar. 31, 2022		49,306,000

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Loss for the period	$ (17,215)	$ (31,566)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets		2
Depreciation of property and equipment	45	15
In-process research and development		16,094
Change in fair value of milestone liability	(10)	14
Interest expense		23
Amortization of deferred loan costs		74
Warrants issued for services	35	438
Stock option expense	2,283	4,248
Changes in operating assets and liabilities
Prepaid expenses, deposits and other	(998)	(2,594)
Accounts payable and accrued liabilities	563	(640)
Related party payables	(103)	(279)
Net cash used in operating activities	(15,400)	(14,171)
Cash flows from investing activities
Cash acquired on merger with Adgero		969
Purchase of equipment		(8)
Proceeds on sale of equipment		3
Net cash provided by investing activities		964
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	13,634	21,598
Warrants exercised for cash	74	4,399
Stock options exercised for cash		42
Proceeds from loan		500
Series A preferred cash dividend	(6)	(6)
Net cash provided by financing activities	13,702	26,533
(Decrease) increase in cash and cash equivalents	(1,698)	13,326
Cash and cash equivalents – beginning of period	10,537	2,392
Cash and cash equivalents – end of period	$ 8,839	$ 15,718

Nature of operations, corporate

Nature of operations, corporate history, and going concern and management plans	9 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of operations, corporate history, and going concern and management plans	1 Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. On June 9, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among Adgero Acquisition Corp., the Company’s wholly-owned subsidiary incorporated in the State of Delaware (“Merger Sub”), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”). On August 19, 2020, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into Adgero (the “Merger”), the separate corporate existence of Merger Sub ceased and Adgero continued its existence under Delaware law as the surviving corporation in the Merger and became a direct, wholly-owned subsidiary of the Company. As a result of the Merger, each issued and outstanding share of Adgero common stock, par value $ 0.0001 per share (the “Adgero Common Stock”) (other than treasury shares held by Adgero), was converted automatically into 1.5740 shares (the “Exchange Ratio”) of the Company’s common stock per share of Adgero Common Stock, and cash in lieu of any fractional shares. Also, each outstanding warrant to purchase Adgero Common Stock was converted into a warrant exercisable for that number of shares of the Company’s common stock equal to the product of (x) the aggregate number of shares of Adgero Common Stock for which such warrant was exercisable and (y) the Exchange Ratio. Following the completion of the Merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on Nasdaq under the symbol “KTRA”. Corporate history The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero. References to the Company refer to the Company and its wholly-owned subsidiaries. Going concern and management plans These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the nine months ended March 31, 2022, the Company reported a loss of $ 17,215 and a negative cash flow from operations of $ 15,400 . The Company had an accumulated deficit of $ 130,908 and had cash and cash equivalents of $ 8,839 as of March 31, 2022. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On April 14, 2022, the Company completed a registered direct financing for net proceeds of approximately $ 7.9 million. Even with the proceeds from this financing, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these condensed consolidated interim financial statements. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or the entering into of strategic partnership arrangements but the ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic. The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. These condensed consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Certain prior period balances have been reclassified to conform with the current year’s presentation. Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2021 audited consolidated financial statements of the Company included in the Company’s Form 10-K filed with the SEC on September 28, 2021. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three and nine months ended March 31, 2022 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2022, or for any other future annual or interim period. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the nine-month periods ended March 31, 2022, and 2021, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, and convertible preferred shares is anti-dilutive. As of March 31, 2022, potential common shares of 18,397 (2021 – 8,226 ) related to outstanding common share warrants, 2,100 (2021 – 2,104 ) related to outstanding Series C preferred stock warrants, 9,846 (2021 – 6,453 ) related to stock options, nil (2021 – 150 ) relating to outstanding Series B convertible preferred shares, and 14,496 (2021 – 17,997 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share. Acquired in-process research and development expense The Company acquired in-process research and development assets in connection with its Merger with Adgero (note 3). As the acquired in-process research and development assets were deemed to have no current, or alternative future use, an expense of $ 16,094 was recognized in the condensed consolidated interim statements of operations for the nine-month period ended March 31, 2021. Property, equipment, and intangibles Property, equipment and intangibles are stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of three years . Depreciation expense is recognized from the date the equipment was put into use. Recently adopted accounting standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective July 1, 2022, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on July 1, 2021. The Company adopted ASU 2020-06 effective July 1, 2021. The adoption of ASU 2020-06 did not have a material impact on the Company’s financial statements. Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated interim financial statements.

Merger

Merger	9 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Merger	3 Merger As described in note 1, on August 19, 2020, the Company completed its Merger with Adgero in accordance with the terms of the Merger Agreement. In connection with the Merger, substantially all of the fair value was concentrated in in-process research and development (“IPR&D”). As such, the Merger has been treated as an acquisition of Adgero assets and an assumption of Adgero liabilities. Under the terms of the Merger Agreement, upon closing of the Merger, the Company issued 11,439 shares of Company common stock and 2,314 stock purchase warrants (“Adgero Warrants”) to the security holders of Adgero. The Adgero Warrants are exercisable at $ 3.18 per share (note 6). Also, in conjunction with the Merger, the Company issued 572 shares of common stock to the placement agent as a success fee. The aggregate fair value of consideration transferred to the Adgero shareholders was $ 16,724 . As part of the Merger, the Company acquired in-process research and development of $ 16,094 and other net assets of $ 630 . The fair value of the acquired in-process research and development assets has been expensed as a charge in the condensed consolidated interim statements of operations for the nine months ended March 31, 2021, as there is no alternative use for these assets. The Company incurred approximately $ 1,554 of legal, consulting and other professional fees related to the Merger of which approximately $ 500 was incurred during the nine months ended March 31, 2021. The transaction costs have been classified as merger expenses in the condensed consolidated statement of operations. In connection with the Merger, the Company recorded a milestone payment liability which relates to an asset purchase agreement with St. Cloud Investments, LLC (“St. Cloud”) that Adgero has regarding the acquisition of REM-001. The Agreement, as amended, is dated November 26, 2012 (the “St. Cloud Agreement”). Pursuant to the terms of the St. Cloud Agreement, the Company is obligated to make certain payments under the agreement. The future contingent amounts payable under that agreement are as follows:  Upon the earlier of (i) a subsequent equity financing to take place after the Company conducts a Phase 2B clinical study in which 50 patients complete the study and their clinical data can be evaluated or (ii) the commencement of a clinical study intended to be used as a definitive study for market approval in any country, the Company is obligated to pay an aggregate amount of $ 300 in cash or an equivalent amount of common stock, with $ 240 to St. Cloud and $ 60 to a former employee of the Company; and  Upon receipt of regulatory approval of REM-001 Therapy, the Company is obligated to pay an aggregate amount of $ 700 in cash or an equivalent amount of common stock, with $ 560 to St. Cloud and $ 140 to a former employee of the Company. With respect to the $300 and $700 potential milestone payments referenced above (each a “Milestone Payment”), if either such Milestone Payment becomes payable, and in the event the Company elects to pay either such Milestone Payment in shares of its common stock, the value of the common stock will equal the average of the closing price per share of the Company’s common stock over the twenty (20) trading days following the first public announcement of the applicable event described above. As of March 31, 2022, the Company reviewed its estimates with respect to the planned timing of completion of the respective milestones and adjusted the liability accordingly. $ Balance – June 30, 2021 182 Change in fair value estimate ( 10 ) Balance – March 31, 2022 172

Clinical Trial Deposit

Clinical Trial Deposit	9 Months Ended
	Mar. 31, 2022
Other Liabilities [Abstract]
Clinical Trial Deposit	4 Clinical trial deposit In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registration study for glioblastoma multiforme. Under the agreement, the Company will supply the drug for the study and the CRO will manage all operational aspects of the study including site activation and patient enrollment. The Company is required to make certain payments under the agreement related to patient enrollment milestones. For the three and nine months ended March 31, 2022, the Company has recognized $ 1,840 (2021 – $ 1,708 ) and $ 5,770 (2021 – $ 2,958 ), respectively, of expenses for this study in relation to clinical site initiation and patient enrollment. In relation to this study, the Company has made a deposit payment of $ 2,600 to the CRO. It is anticipated that the deposit will be applied to future invoices, or refunded to the Company, beyond twelve months from March 31, 2022. The Company can terminate the study at any time. Upon termination, the Company will be liable for any payments due to the effective date of the termination as well as any non-refundable costs incurred by the CRO prior to the date of termination.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related party transactions	5 Related party transactions Valent Technologies, LLC Agreements One of the Company’s officers is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279 (including aggregate accrued interest to September 30, 2014, of $ 29 ), issued to Valent by Del Mar (BC), for 279 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. For the three months ended March 31, 2022, and 2021, respectively, the Company recorded $ 2 related to the dividend paid to Valent, while for the nine months ended March 31, 2022, and 2021, respectively, the Company recorded $ 6 related to the dividend paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. Related party payables As of March 31, 2022, there is an aggregate amount of $ 458 (June 30, 2021 - $ 561 ) payable to the Company’s officers and directors for fees, expenses, and accrued bonuses and other liabilities.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	6 Stockholders’ equity Preferred stock Series C Preferred Stock Series C Preferred Stock Number $ Balance – June 30, 2021 20,092 14,652 Conversion of Series C Preferred stock to common stock ( 3,254 ) ( 2,377 ) Balance – March 31, 2022 16,838 12,275 In connection with the Merger (note 3), in August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of $ 1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are $ 1.16 , $ 1.214 , and $ 1.15 , respectively. Subject to ownership limitations, the owners of the Series C Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10 %, 15 %, 20 % and 25 % of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12 th , 24 th , 36 th and 48 th month, anniversary of the initial closing of the private placement which occurred on August 19, 2020. The Series C Preferred Stock dividends do not require declaration by the Board of Directors and are accrued annually as of the date the dividend is earned in an amount equal to the fair value of the Company’s common stock on the dates the respective dividends are paid. The fair value of the Series C Preferred Stock dividend paid on August 19, 2021, was determined by multiplying the dividends paid of 1,698 by the Company’s closing share price on August 19, 2021, of $ 1.45 per share for a total fair value of $ 2,462 . Any outstanding shares of Series C Preferred Stock will automatically convert to shares of common stock on August 19, 2024. Total gross proceeds from the private placement were $ 25,028 , or approximately $ 21,573 in net proceeds after deducting financing costs of $ 3,455 with respect to agent commissions and expenses, as well as legal and accounting fees. In addition, the Company issued 2,504 Series C Preferred Stock purchase warrants with a fair value of $ 3,287 to the placement agent (“Series C Agent Warrants”). The Company’s Series C Preferred Stock outstanding, conversion shares, and aggregate dividends as of March 31, 2022, are as follows: Series Number Conversion Number of Dividend Shares (in thousands) Series 1 13,945 1.16 12,022 8,641 Series 2 898 1.21 740 518 Series 3 1,995 1.15 1,734 1,237 16,838 14,496 10,396 Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 1,698 15% - August 19, 2022 (estimated) 2,174 20% - August 19, 2023 (estimated) 2,899 25% - August 19, 2024 (estimated) 3,625 10,396 The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $ 3,181 related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share for the nine months ended March 31, 2021. The Series C Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock shall be pari passu in liquidation to the Company’s Series A Preferred Stock. The liquidation value of the Series C Preferred Stock at March 31, 2022, is the stated value of $ 16,838 (June 30, 2021 - $ 20,092 ). Series B Preferred Stock During the year ended June 30, 2016, the Company issued 902 shares of Series B Preferred Stock. The remaining balance of 601 shares of Series B Preferred Stock were fully converted to 150 shares of common stock on April 29, 2021. The holders of the Series B Preferred Stock were entitled to an annual cumulative, in arrears, dividend at the rate of 9 % payable quarterly. The 9% dividend accrued quarterly commencing on the date of issue and was payable quarterly on September 30, December 31, March 31, and June 30 of each year commencing on June 30, 2016. Dividends were payable solely by delivery of shares of common stock, in an amount for each holder equal to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided by the conversion price. Pursuant to the Series B Preferred Stock dividend, during the three months ended March 31, 2022, the Company issued nil (2021 – 3 ) shares of common stock and recognized $ nil (2021 - $ 6 ) and during the nine months ended March 31, 2022, the Company issued nil (2021 – 10 ) shares of common stock and recognized $ nil (2021 - $ 15 ). These dividends have been recognized as an increase in accumulated deficit. In addition, the Company and the Series B Preferred Stockholders entered into a royalty agreement, pursuant to which the Company will pay the holders of the Series B Preferred Stock, in aggregate, a single-digit royalty based on their pro rata ownership of the Series B Preferred Stock on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement. Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 279 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $ 1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 5). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock shall be pari passu in liquidation to the Company’s Series C Preferred Stock. The liquidation value of the Series A Preferred stock at March 31, 2022 is its stated value of $ 279 (June 30, 2021 - $ 279 ). There was no change to the Series A Preferred stock for the three or nine months ended March 31, 2022 or 2021. Common stock Stock issuances during the nine months ended March 31, 2022 Registered direct financing On September 28, 2021, the Company closed on the sale of (i) 7,200 shares of its common stock, par value $ 0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 4,800 shares of common stock and (iii) common warrants to purchase an aggregate of 12,000 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $1.25 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $ 7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55 %, a contractual term of 3.5 years, a volatility of 116.7 %, and a dividend rate of 0 %. The estimated volatility of the Company’s common stock is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the contractual life of the instrument at the valuation date. The term is based on the contractual term of the warrant. The net proceeds from the September Offering were $ 13,634 after deducting commissions and other offering expenses. The 2022 Investor Warrants are exercisable at $1.25 per share until their expiry on March 28, 2025 , and the PFW are exercisable at $0.001 per share at any time after September 28, 2021. The Company also issued 600 agent warrants that are exercisable at $ 1.5265 per share commencing September 28, 2021 , until their expiry on March 28, 2025 (the “2022 Agent Warrants”). The 2022 Agent Warrants have been valued at $ 333 and have been treated as non-cash issue costs of the common stock, 2022 Investor Warrants, and PFW. The 2022 Agent Warrants have been valued using a Black-Scholes valuation with a risk-free rate of 0.55 %, a contractual term of 3.5 years, a volatility of 116.7 %, and a dividend rate of 0 %. The estimated volatility of the Company’s common stock is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the contractual life of the instrument at the valuation date. The term is based on the contractual term of the warrant . During the nine months ended March 31, 2022, all of the 4,800 PFW were exercised at $ 0.001 per PFW for proceeds of $ 4.8 . Stock options 2017 Omnibus Incentive Plan As subsequently approved by the Company’s stockholders at an annual meeting of stockholders on April 11, 2018, the Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) under the 2017 Plan. As approved by the Company’s stockholders on June 25, 2021, the number of common shares available under the 2017 Plan is 13,000 shares. Under the 2017 Plan, 13,000 shares of Company common stock are currently reserved for issuance, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised. A total of 120 shares of common stock have been issued under the Legacy Plan and/or are subject to outstanding stock options granted under the Legacy Plan, and a total of 9,726 shares of common stock have been issued under the 2017 Plan and/or are subject to outstanding stock options granted under the 2017 Plan leaving 2,960 shares of common stock available at March 31, 2022 for issuance under the 2017 Plan if all such options under the Legacy Plan were exercised, net of stock options previously exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8 % of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027. During the nine months ended March 31, 2022, a total of 3,954 stock options to purchase shares of common stock were granted to directors and an officer of the Company. Of the total stock options granted, 435 have an exercise price of $ 1.24 per share and vest in 12 equal monthly installments beginning on October 22, 2021. The remaining 3,519 stock options granted have an exercise price of $ 0.96 per share and vest as to 25% on November 8, 2022, with the remaining portion vesting in equal monthly installments over a period of 36 months commencing on December 8, 2022. All of the options to purchase shares of common stock granted have a 10 -year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. In addition, 2,715 stock options previously issued to an officer of the Company were modified such that 754 stock options that were to vest over the period December 15, 2022, to September 15, 2023, now vest on a contingent basis dependent on the achievement of certain strategic partnership initiatives. In relation to the termination of an officer of the Company, the Company has recognized $31 in stock option expense due to the acceleration of vesting of certain stock options granted to that officer. The following table sets forth changes in stock options outstanding under all plans: Number of Weighted Balance – June 30, 2021 6,392 2.26 Granted 3,964 0.99 Expired ( 28 ) 15.45 Forfeited ( 482 ) 1.64 Balance – March 31, 2022 9,846 1.74 The following table summarizes stock options outstanding and exercisable under all plans at March 31, 2022: Exercise price Number Weighted Number 0.33 10 9.96 — 0.61 816 7.43 781 0.74 250 7.61 125 0.96 3,519 9.60 — 1.24 368 9.48 201 1.36 300 8.48 150 1.37 75 9.08 — 1.70 4,283 8.46 2,578 6.10 17 6.60 17 8.70 12 5.59 12 9.83 83 6.14 83 10.60 4 6.03 4 11.70 30 0.91 30 15.99 2 0.21 2 21.10 7 5.27 7 29.60 2 2.84 2 37.60 5 3.86 5 41.00 4 4.61 4 42.00 30 1.37 30 44.80 3 3.86 3 49.50 13 4.88 13 53.20 8 4.10 8 61.60 2 1.00 2 92.00 3 1.17 3 9,846 4,060 Included in the number of stock options outstanding are 2.0 stock options granted at an exercise price of CA$20.00. The exercise price of these options shown in the above table have been converted to US $ 15.99 per share using the period ending closing exchange rate. Stock options granted during the nine months ended March 31, 2022, have been valued using a Black-Scholes pricing model with the following assumptions: March 31, 2022 Dividend rate — % Estimated volatility 91.71 % Risk-free rate 1.78 % Expected term – years 5.99 The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining term of the stock options at the valuation date. The expected term of the stock options has been estimated using the plain vanilla method. The Company has recognized the following amounts as stock option expense for the periods noted (in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Research and development ( 29 ) 508 464 1,171 General and administrative 671 1,210 1,819 3,077 642 1,718 2,283 4,248 All of the stock option expense for the periods ended March 31, 2022, and 2021, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding at March 31, 2022 was $ nil (2021 - $ 1,618 ) and the aggregate intrinsic value of stock options exercisable at March 31, 2022 was $ nil (2021 - $ 1,044 ). As of March 31, 2022, there was $ 2,961 in unrecognized compensation expense that will be recognized over the next 3.96 years. The following table sets forth changes in unvested stock options under all plans: Number of Weighted Unvested at June 30, 2021 3,860 1.60 Granted 3,964 0.99 Vested ( 1,556 ) 1.55 Forfeited ( 482 ) 1.64 Unvested at March 31, 2022 5,786 1.19 The aggregate intrinsic value of unvested stock options at March 31, 2022 was $ nil (2021 - $ 573 ). The unvested stock options have a remaining weighted average contractual term of 9.17 years (2021 – 9.39 ). Common stock warrants The following table sets forth changes in outstanding common stock warrants: Number of Weighted Balance – June 30, 2021 6,974 3.34 Issuance of 2022 Investor Warrants 12,000 1.25 Issuance of PFW 4,800 0.001 Issuance of 2022 Agent Warrants 600 1.5625 Exercise of PFW ( 4,800 ) 0.001 Exercise of 2020 Investor Warrants ( 69 ) 1.00 Expiry of Adgero replacement warrants ( 1,108 ) 3.18 Balance – March 31, 2022 18,397 1.94 The following table summarizes the Company’s outstanding common stock warrants as of March 31, 2022: Description of warrants Number Exercise Expiry date 2022 Investor warrants 12,000 1.25 March 28, 2025 2020 Investor warrants 3,264 1.00 August 16, 2024 2019 Investor warrants 760 3.10 June 5, 2024 2018 Investor warrants 280 12.50 September 22, 2022 2017 Investor warrants 208 35.00 April 19, 2022 NBTS Warrants 125 1.09 June 19, 2025 (i) Warrants issued for services 6 17.80 January 25, 2023 Warrants issued for services 34 11.70 February 27, 2023 Warrants issued for services 14 9.00 September 15, 2023 Warrants issued for services 280 0.75 November 18, 2023 Warrants issued for services 125 0.64 January 20, 2024 Warrants issued for services 330 1.49 September 22, 2023 Warrants issued for services 50 1.82 November 13, 2023 Warrants issued for services 100 1.47 January 7, 2024 Warrants issued for services 70 2.75 February 17, 2024 Warrants issued for services 50 2.38 February 25, 2024 2022 Agent warrants 600 1.56 March 28, 2025 2019 Agent warrants 47 3.88 June 3, 2024 2018 Agent warrants 40 12.50 September 20, 2022 2017 Agent warrants 14 40.60 April 12, 2022 18,397 Series C Preferred Stock warrants In connection with the Series C Preferred Stock private placement, the Company issued 2,504 Series C Agent Warrants. The Series C Agent Warrants have an exercise price of $ 1,000 per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series. The Series C Agent Warrants were valued at a total of $ 3,287 using a binomial pricing model with a risk-free interest rate of 0.27 %, a term of 4.0 years, and a volatility of 95.2 % to 95.8 %. The estimated volatility of the Company’s common stock at the date of measurement is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the instrument at the valuation date. The expected term has been estimated using the contractual term of the warrant. The following table sets forth changes in outstanding Series C Agent Warrants: Balance Number of Number of Balance, Conversion Preferred Series C-1 Agent Warrants 1,929 — — 1,929 1.16 Preferred Series C-2 Agent Warrants 219 — — 219 1.21 Preferred Series C-3 Agent Warrants 296 — — 296 1.15 2,444 — — 2,444 The following table summarizes the Company’s outstanding Series C Agent Warrants as of March 31, 2022: Series C Agent Warrants Number Conversion Number of Cumulative Series 1 1,929 1.16 1,663 1,164 Series 2 219 1.21 180 126 Series 3 296 1.15 257 180 2,444 2,100 1,470

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	9 Months Ended
	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information	7 Supplementary statement of cash flows information The Company incurred the following non-cash investing and financing transactions (in thousands): Nine months ended March 31, March 31, Series C Preferred Stock common stock dividend (note 6) 2,462 — Series B Preferred Stock common stock dividend (note 6) — 15 Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 6) — 3,181 Non-cash issue costs (note 6) 333 3,287 Cashless exercise of Series C warrants (note 6) — 71 Income taxes paid — — Interest paid — —

Financial instruments

Financial instruments	9 Months Ended
	Mar. 31, 2022
Investments All Other Investments [Abstract]
Financial Instruments	8 Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:  Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;  Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and  Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As at March 31, 2022, the Company’s milestone payment liability was measured using level 3 inputs (note 3). March 31, 2022 Liability Level 1 Level 2 Level 3 Milestone payment liability — — 172 The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent events	9 Subsequent events Registered direct financing On April 14, 2022, the Company closed on the sale of 16,266 shares of its common stock, par value $ 0.001 per share, and common warrants to purchase an aggregate of 16,266 shares of common stock (“2022 April Investor Warrants”) in the Company’s registered direct offering (the “April Offering”). Each share of common stock was sold together with a 2022 April Investor Warrant to purchase one share of common stock at a combined effective price of $0.53 per share of common stock and accompanying 2022 April Investor Warrant. The net proceeds from the April Offering were approximately $ 7,900 after deducting commissions and other offering expenses. The 2022 April Investor Warrants are exercisable at $0.41 per share until their expiry on April 14, 2027 . The Company also issued 811 agent warrants that are exercisable at $ 0.6625 per share commencing October 14, 2022 , until their expiry on October 14, 2026 . Warrants and stock options Subsequent to March 31, 2022, a total of 222 common stock warrants exercisable at a weighted average price of $ 35.35 per share expired and 280 stock options exercisable at a weighted average exercise price of $ 1.65 expired. The Company has evaluated its subsequent events from March 31, 2022, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted above.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented. Certain prior period balances have been reclassified to conform with the current year’s presentation.
Unaudited Interim Financial Data	Unaudited interim financial data The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2021 audited consolidated financial statements of the Company included in the Company’s Form 10-K filed with the SEC on September 28, 2021. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three and nine months ended March 31, 2022 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2022, or for any other future annual or interim period.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.
Loss Per Share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the nine-month periods ended March 31, 2022, and 2021, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, and convertible preferred shares is anti-dilutive. As of March 31, 2022, potential common shares of 18,397 (2021 – 8,226 ) related to outstanding common share warrants, 2,100 (2021 – 2,104 ) related to outstanding Series C preferred stock warrants, 9,846 (2021 – 6,453 ) related to stock options, nil (2021 – 150 ) relating to outstanding Series B convertible preferred shares, and 14,496 (2021 – 17,997 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.
Acquired In-process Research And Development Expense	Acquired in-process research and development expense The Company acquired in-process research and development assets in connection with its Merger with Adgero (note 3). As the acquired in-process research and development assets were deemed to have no current, or alternative future use, an expense of $ 16,094 was recognized in the condensed consolidated interim statements of operations for the nine-month period ended March 31, 2021.
Property, equipment and intangibles	Property, equipment, and intangibles Property, equipment and intangibles are stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of three years . Depreciation expense is recognized from the date the equipment was put into use.
Recent Accounting Standards	Recently adopted accounting standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective July 1, 2022, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on July 1, 2021. The Company adopted ASU 2020-06 effective July 1, 2021. The adoption of ASU 2020-06 did not have a material impact on the Company’s financial statements. Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated interim financial statements.

Merger (Tables)

Merger (Tables)	9 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Schedule of Milestone Payment Liability	As of March 31, 2022, the Company reviewed its estimates with respect to the planned timing of completion of the respective milestones and adjusted the liability accordingly.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2022
Class Of Stock [Line Items]
Schedule of Stock Option Expense	Three months ended Nine months ended 2022 2021 2022 2021 Research and development ( 29 ) 508 464 1,171 General and administrative 671 1,210 1,819 3,077 642 1,718 2,283 4,248
Schedule of Unvested Stock Options	Number of Weighted Unvested at June 30, 2021 3,860 1.60 Granted 3,964 0.99 Vested ( 1,556 ) 1.55 Forfeited ( 482 ) 1.64 Unvested at March 31, 2022 5,786 1.19
Schedule of Warrants	Number of Weighted Balance – June 30, 2021 6,974 3.34 Issuance of 2022 Investor Warrants 12,000 1.25 Issuance of PFW 4,800 0.001 Issuance of 2022 Agent Warrants 600 1.5625 Exercise of PFW ( 4,800 ) 0.001 Exercise of 2020 Investor Warrants ( 69 ) 1.00 Expiry of Adgero replacement warrants ( 1,108 ) 3.18 Balance – March 31, 2022 18,397 1.94
Schedule of Changes in Outstanding Warrants	Description of warrants Number Exercise Expiry date 2022 Investor warrants 12,000 1.25 March 28, 2025 2020 Investor warrants 3,264 1.00 August 16, 2024 2019 Investor warrants 760 3.10 June 5, 2024 2018 Investor warrants 280 12.50 September 22, 2022 2017 Investor warrants 208 35.00 April 19, 2022 NBTS Warrants 125 1.09 June 19, 2025 (i) Warrants issued for services 6 17.80 January 25, 2023 Warrants issued for services 34 11.70 February 27, 2023 Warrants issued for services 14 9.00 September 15, 2023 Warrants issued for services 280 0.75 November 18, 2023 Warrants issued for services 125 0.64 January 20, 2024 Warrants issued for services 330 1.49 September 22, 2023 Warrants issued for services 50 1.82 November 13, 2023 Warrants issued for services 100 1.47 January 7, 2024 Warrants issued for services 70 2.75 February 17, 2024 Warrants issued for services 50 2.38 February 25, 2024 2022 Agent warrants 600 1.56 March 28, 2025 2019 Agent warrants 47 3.88 June 3, 2024 2018 Agent warrants 40 12.50 September 20, 2022 2017 Agent warrants 14 40.60 April 12, 2022 18,397
Series C Warrants [Member]
Class Of Stock [Line Items]
Schedule of Changes in Outstanding Warrants	Series C Agent Warrants Number Conversion Number of Cumulative Series 1 1,929 1.16 1,663 1,164 Series 2 219 1.21 180 126 Series 3 296 1.15 257 180 2,444 2,100 1,470
Schedule of Conversion of Series C Preferred Stock to Series C Warrants	Balance Number of Number of Balance, Conversion Preferred Series C-1 Agent Warrants 1,929 — — 1,929 1.16 Preferred Series C-2 Agent Warrants 219 — — 219 1.21 Preferred Series C-3 Agent Warrants 296 — — 296 1.15 2,444 — — 2,444
Stock options [Member]
Class Of Stock [Line Items]
Schedule of Outstanding Under the Legacy Plan	Number of Weighted Balance – June 30, 2021 6,392 2.26 Granted 3,964 0.99 Expired ( 28 ) 15.45 Forfeited ( 482 ) 1.64 Balance – March 31, 2022 9,846 1.74
Summary of Stock Options Currently Outstanding and Exercisable	Exercise price Number Weighted Number 0.33 10 9.96 — 0.61 816 7.43 781 0.74 250 7.61 125 0.96 3,519 9.60 — 1.24 368 9.48 201 1.36 300 8.48 150 1.37 75 9.08 — 1.70 4,283 8.46 2,578 6.10 17 6.60 17 8.70 12 5.59 12 9.83 83 6.14 83 10.60 4 6.03 4 11.70 30 0.91 30 15.99 2 0.21 2 21.10 7 5.27 7 29.60 2 2.84 2 37.60 5 3.86 5 41.00 4 4.61 4 42.00 30 1.37 30 44.80 3 3.86 3 49.50 13 4.88 13 53.20 8 4.10 8 61.60 2 1.00 2 92.00 3 1.17 3 9,846 4,060
Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model	March 31, 2022 Dividend rate — % Estimated volatility 91.71 % Risk-free rate 1.78 % Expected term – years 5.99
Performance stock units [Member]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock	Series C Preferred Stock Number $ Balance – June 30, 2021 20,092 14,652 Conversion of Series C Preferred stock to common stock ( 3,254 ) ( 2,377 ) Balance – March 31, 2022 16,838 12,275
Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Aggregate Dividends	The Company’s Series C Preferred Stock outstanding, conversion shares, and aggregate dividends as of March 31, 2022, are as follows: Series Number Conversion Number of Dividend Shares (in thousands) Series 1 13,945 1.16 12,022 8,641 Series 2 898 1.21 740 518 Series 3 1,995 1.15 1,734 1,237 16,838 14,496 10,396 Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 1,698 15% - August 19, 2022 (estimated) 2,174 20% - August 19, 2023 (estimated) 2,899 25% - August 19, 2024 (estimated) 3,625 10,396

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	9 Months Ended
	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplementary Statement of Cash Flows Information	The Company incurred the following non-cash investing and financing transactions (in thousands): Nine months ended March 31, March 31, Series C Preferred Stock common stock dividend (note 6) 2,462 — Series B Preferred Stock common stock dividend (note 6) — 15 Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 6) — 3,181 Non-cash issue costs (note 6) 333 3,287 Cashless exercise of Series C warrants (note 6) — 71 Income taxes paid — — Interest paid — —

Financial instruments (Tables)

Financial instruments (Tables)	9 Months Ended
	Mar. 31, 2022
Investments All Other Investments [Abstract]
Schedule of Assets and Liabilities Classified , Changes in the Observability of Valuation Inputs Measured using Level 3 Inputs	As at March 31, 2022, the Company’s milestone payment liability was measured using level 3 inputs (note 3).

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Going Concern and Management Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Apr. 14, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Aug. 19, 2020
Common stock, par value		$ 0.001		$ 0.001		$ 0.001	$ 0.0001
Conversion of convertible common stock				1.5740 shares
Nature of operations, corporate history, and going concern (Textual)
Net loss		$ (5,356)	$ (6,635)	$ (17,215)	$ (31,566)
Negative cash flow from operations				(15,400)	$ (14,171)
Cash and cash equivalents		8,839		8,839		$ 10,537
Accumulated deficit		$ (130,908)		$ (130,908)		$ (111,225)
Substantial Doubt about Companys Ability to Continues Going Concern Period				1 year
Subsequent Event [Member]
Nature of operations, corporate history, and going concern (Textual)
Proceeds from registered direct financing subsequent	$ 7,900

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
In-process research and development		$ 16,094
Property, equipment and intangibles estimated useful life	3 years
Series C Preferred Share Warrants [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	2,100	2,104
Series B Convertible Preferred Shares [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		150
Series C Convertible Preferred Shares [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	14,496	17,997
Stock options [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	9,846	6,453
Warrant [Member]
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	18,397	8,226

Merger - Additional Information

Merger - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Legal fee		$ 1,554
Professional fees		$ 500
Cash or equivalent to common stock	$ 300
Contingent amounts payable to St. Cloud	240
Cash paid to employees	$ 60
Merger Agreement [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Stock purchase warrants	2,314
Warrants exercisable price	$ 3.18
Fair value of consideration transferred	$ 16,724
Payments to acquire in-process research and development	16,094
Payments to acquire other net assets	$ 630
Merger Agreement [Member] | Common stock
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Number of shares issued	11,439
Merger Agreement [Member] | Common stock | Private Placement [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Merger success fee	572
REM-001 Therapy [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Cash or equivalent to common stock	$ 700
Contingent amounts payable to St. Cloud	560
Cash paid to employees	$ 140

Merger - Schedule of Milestone

Merger - Schedule of Milestone Payment Liability (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)
Business Combinations [Abstract]
Balance	$ 182
Change in fair value estimate	(10)
Balance	$ 172

Clinical Trial Deposit - Additi

Clinical Trial Deposit - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Other Liabilities [Abstract]
Patient enrollment milestones, payments	$ 1,840	$ 1,708	$ 5,770	$ 2,958
Deposits payments			$ 2,600

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Preferred stock, par value		$ 0.001		$ 0.001		$ 0.001
Dividend payable				$ 6	$ 6
Related party payables		$ 458		$ 458		$ 561
Preferred Stock Series A
Preferred Stock, shares issued		279,000		279,000		279,000
Preferred stock, rate of dividend	3.00%
Valent Technologies LLC [Member]
Loan payable outstanding amount	$ 279
Aggregate accrued interest	$ 29
Dividend payable		$ 2	$ 2	$ 6	$ 6
Valent Technologies LLC [Member] | Preferred Stock Series A
Preferred Stock, shares issued	279
Preferred stock, par value	$ 1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Issuance of Series C Preferred Stock (Detail) - Preferred Stock Series C $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)shares
Class Of Stock [Line Items]
Beginning Balance | $	$ 14,652
Beginning Balance, shares | shares	20,092
Conversion of Series C Preferred stock to common stock | $	$ (2,377)
Conversion of series C preferred stock to common stock, shares | shares	(3,254)
Ending Balance | $	$ 12,275
Ending Balance, shares | shares	16,838

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Sep. 28, 2021USD ($)$ / sharesshares	Aug. 19, 2021USD ($)$ / shares	Sep. 30, 2014$ / sharesshares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)shares	Dec. 31, 2020shares	Sep. 30, 2020shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)shares	Jun. 30, 2016shares	Jun. 30, 2021USD ($)$ / sharesshares	Apr. 29, 2021shares
Class Of Stock [Line Items]
Non cash dividends of preferred stock | $									$ 3,181,000
Preferred stock, par value | $ / shares				$ 0.001				$ 0.001			$ 0.001
Underwritten public offering, description								the Company closed on the sale of (i) 7,200 shares of its common stock, par value $0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 4,800 shares of common stock and (iii) common warrants to purchase an aggregate of 12,000 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $1.25 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55%, a contractual term of 3.5 years, a volatility of 116.7%, and a dividend rate of 0%.
Common stock, shares issued				49,306,000				49,306,000			32,740,000
Warrants exercised for cash | $								$ 74,000	$ 4,399,000
Number of options granted								3,964,000
Number of stock options outstanding				9,846,000				9,846,000
Weighted average contractual term								9 years 2 months 1 day	9 years 4 months 20 days
2017 Omnibus Incentive Plan
Class Of Stock [Line Items]
Common stock, shares issued				13,000				13,000
Percentage of fully diluted shares of common stock								8.00%
Common stock, shares outstanding				120				120
Common stock issued under the 2017 Plan				9,726	2,960			9,726	2,960
2017 Omnibus Incentive Plan | Exercise Price of 1.24 [Member]
Class Of Stock [Line Items]
Stock option exercise price | $ / shares								$ 1.24
Two Thousand And Seventeen Omnibus Incentive Plan
Class Of Stock [Line Items]
Stock option vesting description								vest in 12 equal monthly installments beginning on October 22, 2021. The remaining 3,519 stock options granted have an exercise price of $0.96 per share and vest as to 25% on November 8, 2022, with the remaining portion vesting in equal monthly installments over a period of 36 months commencing on December 8, 2022. All of the options to purchase shares of common stock granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. In addition, 2,715 stock options previously issued to an officer of the Company were modified such that 754 stock options that were to vest over the period December 15, 2022, to September 15, 2023, now vest on a contingent basis dependent on the achievement of certain strategic partnership initiatives. In relation to the termination of an officer of the Company, the Company has recognized $31 in stock option expense due to the acceleration of vesting of certain stock options granted to that officer.
Stock option term								10 years
Two Thousand And Seventeen Omnibus Incentive Plan | Exercise Price of 1.24 [Member]
Class Of Stock [Line Items]
Number of options granted								3,954,000
Two Thousand And Seventeen Omnibus Incentive Plan | Exercise Price Of Zero Point Nine Six
Class Of Stock [Line Items]
Stock option exercise price | $ / shares								$ 0.96
Stock options [Member]
Class Of Stock [Line Items]
Risk free rate								1.78%
Expected term								5 years 11 months 26 days
Volatility rate								91.71%
Number of options granted								3,964,000
Number of stock options outstanding				9,846,000				9,846,000			6,392,000
Aggregate intrinsic value of stock options outstanding | $					$ 1,618,000				$ 1,618,000
Aggregate intrinsic value of stock options exercisable | $					$ 1,044,000				1,044,000
Unrecognized compensation expense | $				$ 2,961				$ 2,961
Unrecognized compensation expense, term								3 years 11 months 15 days
Aggregate intrinsic value of unvested stock options | $									573,000
Stock options [Member] | CA$ $20.00 Exercise Price
Class Of Stock [Line Items]
Number of stock options outstanding				2,000				2,000
Stock options exercise price | $ / shares				$ 15.99				$ 15.99
Common stock
Class Of Stock [Line Items]
Convertible preferred stock												150,000
Series B preferred stock dividend, shares					3,000	3,000	4,000
Issued warrants to underwriters	7,200,000
Warrants exercise price | $ / shares	$ 0.001
Pre-Funded Warrants
Class Of Stock [Line Items]
Issued warrants to underwriters	4,800,000
Warrants exercise price | $ / shares				$ 0.001				$ 0.001
Number				4,800,000				4,800,000
Warrants exercised for cash | $								$ 4,800
2022 Investor Warrant [Member]
Class Of Stock [Line Items]
Issued warrants to underwriters	12,000,000
Value of outstanding warrants | $	$ 7,023,000
Risk free rate	0.55%
Expected term	3 years 6 months
Volatility rate	116.70%
Dividend rate	0.00%
Other Underwriting Expense | $	$ 13,634,000
Expiry date	Mar. 28, 2025
Placement Agent | Series C Agent Warrants [Member]
Class Of Stock [Line Items]
Fair value disclosure | $				$ 3,287,000				$ 3,287,000
Warrants outstanding, term				4 years				4 years
Executive Officers And Director | Two Thousand And Seventeen Omnibus Incentive Plan | Exercise Price of 1.24 [Member]
Class Of Stock [Line Items]
Number of options granted								435,000
Executive Officers And Director | Two Thousand And Seventeen Omnibus Incentive Plan | Exercise Price Of Zero Point Nine Six
Class Of Stock [Line Items]
Number of options granted								3,519,000
Measurement Input, Risk Free Interest Rate | Placement Agent | Series C Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants outstanding, measurement input				0.27				0.27
Measurement Input, Price Volatility | Minimum | Placement Agent | Series C Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants outstanding, measurement input				95.2				95.2
Measurement Input, Price Volatility | Maximum | Placement Agent | Series C Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants outstanding, measurement input				95.8				95.8
Preferred Stock Series C
Class Of Stock [Line Items]
Dividends, Preferred Stock | $		$ 1,698,000
Sale of Stock, Price Per Share | $ / shares		$ 1.45
Preferred stock | $		$ 2,462,000		$ 12,275,000				$ 12,275,000			$ 14,652,000
Non cash dividends of preferred stock | $									$ 3,181,000
Liquidation value | $				$ 16,838				$ 16,838			$ 20,092
Preferred Stock, shares issued				17,000				17,000			20,000
Number				16,838,000				16,838,000
Preferred Stock Series C | Placement Agent | Series C Agent Warrants [Member]
Class Of Stock [Line Items]
Shares issued of common stock for services								2,504
Fair value of preferred stock | $								$ 3,287,000
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price | $ / shares				$ 1.16				$ 1.16
Number				13,945,000				13,945,000
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price | $ / shares				$ 1.214				$ 1.214
Number				898,000				898,000
Series C-3 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price | $ / shares				$ 1.15				$ 1.15
Number				1,995,000				1,995,000
Series B Preferred Stock
Class Of Stock [Line Items]
Shares issued of common stock for services										902,000
Convertible preferred stock												601,000
Preferred stock, rate of dividend								9.00%
Series B preferred stock dividend, shares					3,000				10,000
Direct increase in accumulated deficit | $					$ 6,000				$ 15,000
Preferred Stock Series A
Class Of Stock [Line Items]
Preferred stock | $				279,000				279,000			$ 279,000
Liquidation value | $				$ 279,000				$ 279,000			$ 279,000
Preferred stock, rate of dividend			3.00%
Preferred Stock, shares issued				279,000				279,000			279,000
Change in preferred stock | $				$ 0	$ 0			$ 0	$ 0
Preferred Stock Series A | Exchange Agreement [Member]
Class Of Stock [Line Items]
Preferred stock, rate of dividend			3.00%
Preferred Stock, shares issued			279,000
Preferred stock, par value | $ / shares			$ 1
Private Placement [Member] | Preferred Stock Series C
Class Of Stock [Line Items]
Total gross proceeds | $								25,028,000
Net proceeds from private placement | $								21,573,000
Deferred financing costs | $								$ 3,455,000
Private Placement [Member] | Series C Preferred Stock Warrants
Class Of Stock [Line Items]
Shares issued of common stock for services								2,504
Shares issued, price per share | $ / shares				$ 1,000				$ 1,000
Registered direct financing [Member]
Class Of Stock [Line Items]
Underwritten public offering, description								the Company closed on the sale of 16,266 shares of its common stock, par value $0.001 per share, and common warrants to purchase an aggregate of 16,266 shares of common stock (“2022 April Investor Warrants”) in the Company’s registered direct offering (the “April Offering”). Each share of common stock was sold together with a 2022 April Investor Warrant to purchase one share of common stock at a combined effective price of $0.53 per share of common stock and accompanying 2022 April Investor Warrant.
Registered direct financing [Member] | 2022 Investor Warrant [Member]
Class Of Stock [Line Items]
Number	600,000
Registered direct financing [Member] | 2022 Agent Warrants [Member]
Class Of Stock [Line Items]
Warrants exercise price | $ / shares	$ 1.5265
Risk free rate	0.55%
Expected term	3 years 6 months
Volatility rate	116.70%
Dividend rate	0.00%
Expiry date	Sep. 28, 2021
Underwriter warrants commencing date	Mar. 28, 2025
Non cash issue of common stock	333,000
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services								25,028
Shares issued, price per share | $ / shares				$ 1,000				$ 1,000
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | First Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								10.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Second Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								15.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Third Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								20.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Common stock dividends percentage								25.00%

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Aggregate Dividends (Detail) shares in Thousands	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	13,945
Conversion price | $ / shares	$ 1.16
Number of conversion shares (in thousands)	12,022
Dividend Shares (in thousands)	8,641
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	898
Conversion price | $ / shares	$ 1.214
Number of conversion shares (in thousands)	740
Dividend Shares (in thousands)	518
Series C-3 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	1,995
Conversion price | $ / shares	$ 1.15
Number of conversion shares (in thousands)	1,734
Dividend Shares (in thousands)	1,237
Preferred Stock Series C
Class Of Stock [Line Items]
Number	16,838
Number of conversion shares (in thousands)	14,496
Dividend Shares (in thousands)	10,396
Preferred Stock Series C | 10% - August 19, 2021 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	1,698
Preferred Stock Series C | 15% - August 19, 2022 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	2,174
Preferred Stock Series C | 20% - August 19, 2023 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	2,899
Preferred Stock Series C | 25% - August 19, 2024 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	3,625

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Outstanding Under the Legacy Plan (Detail)	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	3,964,000
Ending balance	9,846,000
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	6,392,000
Granted	3,964,000
Expired	(28,000)
Forfeited	(482,000)
Ending balance	9,846,000
Beginning balance | $ / shares	$ 2.26
Granted | $ / shares	0.99
Expired | $ / shares	15.45
Forfeited | $ / shares	1.64
Ending balance | $ / shares	$ 1.74

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail)	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	9,846,000
Stock options exercisable	4,060,000
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 0.33
Number of stock options outstanding	10,000
Weighted average remaining contractual life (years)	9 years 11 months 15 days
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 0.61
Number of stock options outstanding	816,000
Weighted average remaining contractual life (years)	7 years 5 months 4 days
Stock options exercisable	781,000
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 0.74
Number of stock options outstanding	250,000
Weighted average remaining contractual life (years)	7 years 7 months 9 days
Stock options exercisable	125,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 0.96
Number of stock options outstanding	3,519,000
Weighted average remaining contractual life (years)	9 years 7 months 6 days
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 1.24
Number of stock options outstanding	368,000
Weighted average remaining contractual life (years)	9 years 5 months 23 days
Stock options exercisable	201,000
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 1.36
Number of stock options outstanding	300,000
Weighted average remaining contractual life (years)	8 years 5 months 23 days
Stock options exercisable	150
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 1.37
Number of stock options outstanding	75,000
Weighted average remaining contractual life (years)	9 years 29 days
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 1.70
Number of stock options outstanding	4,283,000
Weighted average remaining contractual life (years)	8 years 5 months 15 days
Stock options exercisable	2,578,000
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 6.10
Number of stock options outstanding	17,000
Weighted average remaining contractual life (years)	6 years 7 months 6 days
Stock options exercisable	17,000
Exercise Price Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 8.70
Number of stock options outstanding	12,000
Weighted average remaining contractual life (years)	5 years 7 months 2 days
Stock options exercisable	12,000
Exercise Price Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 9.83
Number of stock options outstanding	83,000
Weighted average remaining contractual life (years)	6 years 1 month 20 days
Stock options exercisable	83,000
Exercise Price Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 10.60
Number of stock options outstanding	4,000
Weighted average remaining contractual life (years)	6 years 10 days
Stock options exercisable	4,000
Exercise Price Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 11.70
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	10 months 28 days
Stock options exercisable	30,000
Exercise Price Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 15.99
Number of stock options outstanding	2,000
Weighted average remaining contractual life (years)	2 months 15 days
Stock options exercisable	2,000
Exercise Price Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 21.10
Number of stock options outstanding	7,000
Weighted average remaining contractual life (years)	5 years 3 months 7 days
Stock options exercisable	7,000
Exercise Price Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 29.60
Number of stock options outstanding	2,000
Weighted average remaining contractual life (years)	2 years 10 months 2 days
Stock options exercisable	2,000
Exercise Price Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 37.60
Number of stock options outstanding	5,000
Weighted average remaining contractual life (years)	3 years 10 months 9 days
Stock options exercisable	5,000
Exercise Price Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 41
Number of stock options outstanding	4,000
Weighted average remaining contractual life (years)	4 years 7 months 9 days
Stock options exercisable	4,000
Exercise Price Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 42
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	1 year 4 months 13 days
Stock options exercisable	30,000
Exercise Price Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 44.80
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	3 years 10 months 9 days
Stock options exercisable	3,000
Exercise Price Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 49.50
Number of stock options outstanding	13,000
Weighted average remaining contractual life (years)	4 years 10 months 17 days
Stock options exercisable	13,000
Exercise Price Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 53.20
Number of stock options outstanding	8,000
Weighted average remaining contractual life (years)	4 years 1 month 6 days
Stock options exercisable	8,000
Exercise Price Twenty Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 61.60
Number of stock options outstanding	2,000
Weighted average remaining contractual life (years)	1 year
Stock options exercisable	2,000
Exercise Price Twenty Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable price | $ / shares	$ 92
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	1 year 2 months 1 day
Stock options exercisable	3,000

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model (Detail) - Stock options [Member]	9 Months Ended
	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate	91.71%
Risk free rate	1.78%
Expected term	5 years 11 months 26 days

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Stock Option Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 642	$ 1,718	$ 2,283	$ 4,248
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	(29)	508	464	1,171
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 671	$ 1,210	$ 1,819	$ 3,077

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Unvested Stock Options (Detail)	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Equity [Abstract]
Beginning balance | shares	3,860,000
Granted | shares	3,964,000
Vested | shares	(1,556,000)
Forfeited | shares	(482,000)
Ending balance | shares	5,786,000
Beginning balance | $ / shares	$ 1.60
Granted | $ / shares	0.99
Vested | $ / shares	1.55
Forfeited | $ / shares	1.64
Ending balance | $ / shares	$ 1.19

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Warrants (Detail) - Common Stock Warrants [Member]	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Balance – June 30, 2021 | shares	6,974,000
Issuance of 2022 Investor Warrants | shares	12,000,000
Issuance of PFW | shares	4,800,000
Issuance of 2022 Agent Warrants | shares	600,000
Exercise of PFW | shares	(4,800,000)
Exercise of 2020 Investor Warrants | shares	(69,000)
Expiry of Adgero replacement warrants | shares	(1,108,000)
Balance - March 31, 2022 | shares	18,397,000
Beginning balance | $ / shares	$ 3.34
Issuance of 2022 Investor Warrants | $ / shares	1.25
Issuance of PFW | $ / shares	0.001
Issuance of 2022 Agent Warrants | $ / shares	1.5625
Exercise of PFW | $ / shares	0.001
Stock option exercise price | $ / shares	1
Expiry of Adgero replacement warrants | $ / shares	3.18
Ending balance | $ / shares	$ 1.94

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Outstanding Warrants (Detail) - Warrant [Member]	9 Months Ended
	Mar. 31, 2022$ / sharesshares
Number	18,397,000
Issued For Services One [Member]
Number	6,000
Warrants exercise price | $ / shares	$ 17.80
Expiry date	Jan. 25, 2023
Issued For Services Two [Member]
Number	34,000
Warrants exercise price | $ / shares	$ 11.70
Expiry date	Feb. 27, 2023
Issued For Services Three [Member]
Number	14,000
Warrants exercise price | $ / shares	$ 9
Expiry date	Sep. 15, 2023
Issued For Services Four [Member]
Number	280,000
Warrants exercise price | $ / shares	$ 0.75
Expiry date	Nov. 18, 2023
Issued For Services Five [Member]
Number	125,000
Warrants exercise price | $ / shares	$ 0.64
Expiry date	Jan. 20, 2024
Issued For Services Six [Member]
Number	330,000
Warrants exercise price | $ / shares	$ 1.49
Expiry date	Sep. 22, 2023
Issued For Services Seven [Member]
Number	50,000
Warrants exercise price | $ / shares	$ 1.82
Expiry date	Nov. 13, 2023
Issued For Services Eight [Member]
Number	100,000
Warrants exercise price | $ / shares	$ 1.47
Expiry date	Jan. 7, 2024
Issued For Services Nine [Member]
Number	70,000
Warrants exercise price | $ / shares	$ 2.75
Expiry date	Feb. 17, 2024
Issued For Services Ten [Member]
Number	50,000
Warrants exercise price | $ / shares	$ 2.38
Expiry date	Feb. 25, 2024
Investor [Member]
Number	12,000,000
Warrants exercise price | $ / shares	$ 1.25
Expiry date	Mar. 28, 2025
InvestorOne [Member]
Number	3,264,000
Warrants exercise price | $ / shares	$ 1
Expiry date	Aug. 16, 2024
InvestorTwo [Member]
Number	760,000
Warrants exercise price | $ / shares	$ 3.10
Expiry date	Jun. 5, 2024
Investor Three [Member]
Number	280,000
Warrants exercise price | $ / shares	$ 12.50
Expiry date	Sep. 22, 2022
Investor Four [Member]
Number	208,000
Warrants exercise price | $ / shares	$ 35
Expiry date	Apr. 19, 2022
NBTS [Member]
Number	125,000
Warrants exercise price | $ / shares	$ 1.09
Expiry date	Jun. 19, 2025
Agent [Member]
Number	600,000
Warrants exercise price | $ / shares	$ 1.56
Expiry date	Mar. 28, 2025
Agent One [Member]
Number	47,000
Warrants exercise price | $ / shares	$ 3.88
Expiry date	Jun. 3, 2024
Agent Two [Member]
Number	40,000
Warrants exercise price | $ / shares	$ 12.50
Expiry date	Sep. 20, 2022
Agent Three [Member]
Number	14,000
Warrants exercise price | $ / shares	$ 40.60
Expiry date	Apr. 12, 2022

Stockholders' Equity - Schedu_9

Stockholders' Equity - Schedule of Outstanding Series C Preferred Stock Warrants (Detail) - Series C Warrants [Member]	9 Months Ended
	Mar. 31, 2022Warrant$ / sharesshares
Balance	2,444
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	2,444
Preferred Series C-1 Agent Warrants [Member]
Balance	1,929
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	1,929
Warrants exercise price | $ / shares	$ 1.16
Preferred Series C-2 Agent Warrants [Member]
Balance	219
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	219
Warrants exercise price | $ / shares	$ 1.21
Preferred Series C-3 Agent Warrants [Member]
Balance	296
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	296
Warrants exercise price | $ / shares	$ 1.15

Stockholders' Equity - Sched_10

Stockholders' Equity - Schedule of Outstanding Series C Agent Warrants (Detail) - Series C Warrants [Member] - $ / shares	9 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Number	2,444	2,444
Number of conversion shares (in thousands)	2,100,000
Cumulative common stock dividends	1,470,000
Series 1 Warrants Outstanding
Number	1,929
Warrants exercise price	$ 1.16
Number of conversion shares (in thousands)	1,663,000
Cumulative common stock dividends	1,164,000
Series 2 Warrants Outstanding Member
Number	219
Warrants exercise price	$ 1.21
Number of conversion shares (in thousands)	180,000
Cumulative common stock dividends	126,000
Series 3 Warrants Outstanding
Number	296
Warrants exercise price	$ 1.15
Number of conversion shares (in thousands)	257,000
Cumulative common stock dividends	180,000

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information - Schedule of Supplementary Statement of Cash Flows Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 6)			$ 3,181
Non-cash issue costs (note 6)		$ 333	3,287
Preferred Stock Series C
Supplemental Cash Flow Elements [Abstract]
Preferred Stock common stock dividend (note 7)		$ 2,462
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 6)			3,181
Series B Preferred Stock
Supplemental Cash Flow Elements [Abstract]
Preferred Stock common stock dividend (note 7)	$ 6		15
Series C Warrants
Supplemental Cash Flow Elements [Abstract]
Cashless exercise of Series C warrants (note 6)			$ 71

Financial instruments -Schedule

Financial instruments -Schedule of Assets and Liabilities Classified , Changes in the Observability of Valuation Inputs Measured using Level 3 Inputs (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Milestone payment liability	$ 172

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Apr. 14, 2022	Sep. 28, 2021	May 13, 2022	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2022
Subsequent Event [Line Items]
Underwritten public offering, description						the Company closed on the sale of (i) 7,200 shares of its common stock, par value $0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 4,800 shares of common stock and (iii) common warrants to purchase an aggregate of 12,000 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $1.25 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55%, a contractual term of 3.5 years, a volatility of 116.7%, and a dividend rate of 0%.
Stock options exercisable						4,060,000
Registered Direct Financing
Subsequent Event [Line Items]
Underwritten public offering, description						the Company closed on the sale of 16,266 shares of its common stock, par value $0.001 per share, and common warrants to purchase an aggregate of 16,266 shares of common stock (“2022 April Investor Warrants”) in the Company’s registered direct offering (the “April Offering”). Each share of common stock was sold together with a 2022 April Investor Warrant to purchase one share of common stock at a combined effective price of $0.53 per share of common stock and accompanying 2022 April Investor Warrant.
Warrant [Member]
Subsequent Event [Line Items]
Number						18,397,000
Common stock
Subsequent Event [Line Items]
Issued warrants to underwriters		7,200,000
Warrants exercise price		$ 0.001
Stock options exercised, Shares				34,000	35,000
2022 Investor Warrant
Subsequent Event [Line Items]
Issued warrants to underwriters		12,000,000
Other Underwriting Expense		$ 13,634
Expiry date		Mar. 28, 2025
2022 Investor Warrant | Registered Direct Financing
Subsequent Event [Line Items]
Number		600,000
Subsequent Event
Subsequent Event [Line Items]
Stock options exercised, Shares			280,000
Stock options exercise price			$ 1.65
Subsequent Event | Warrant [Member]
Subsequent Event [Line Items]
Stock options exercisable			222,000
Stock options, exercisable expired or forfeited, price			$ 35.35
Subsequent Event | Common stock
Subsequent Event [Line Items]
Issued warrants to underwriters	16,266,000
Warrants exercise price	$ 0.001
Subsequent Event | 2022 Investor Warrant
Subsequent Event [Line Items]
Issued warrants to underwriters	16,266,000
Other Underwriting Expense	$ 7,900
Expiry date	Apr. 14, 2027
Subsequent Event | 2022 Investor Warrant | Registered Direct Financing
Subsequent Event [Line Items]
Warrants exercise price	$ 0.6625
Expiry date	Oct. 14, 2022
Number	811,000
Underwriter warrants commencing date	Oct. 14, 2026